Temozolomide and capecitabine regimen as first-line treatment in advanced gastroenteropancreatic neuroendocrine tumors at a Latin American reference center

Table 1 Demographic and clinical features, n (%)

Feature	n = 38
Age at diagnosis (years)
Median (min-max)	52 (24-77)
Sex
Female	21 (55.3)
Male	17 (44.7)
Region of birth
Lima	14 (36.8)
Huánuco	5 (13.2)
Ancash	3 (7.9)
Ica	3 (7.9)
Junín	3 (7.9)
Lambayeque	2 (5.3)
Ayacucho	2 (5.3)
Cajamarca	2 (5.3)
Amazonas	1 (2.6)
Cusco	1 (2.6)
Puno	1 (2.6)
Tacna	1 (2.6)
BMI, kg/m2
Median (IQR)	23.438 (20.65-26.279)
ECOG scale
0	1 (2.6)
1	35 (92.1)
2	2 (5.3)
Symptoms
Abdominal pain	31 (81.6)
Rectal bleeding	12 (31.6)
Weight loss	9 (23.7)
Diarrhea	5 (13.2)
Emesis	4 (10.5)
Flushing	2 (5.3)

IQR: Interquartile range; BMI: Body mass index; ECOG: Eastern Cooperative Oncology Group.